Sugi Predict

Sugi Predict / Compounds / SCHEMBL20135369

SCHEMBL20135369

SCHEMBL20135369

CC(C)[C@]1(c2ccc(C(=O)N3CCC(c4nc5ccccc5n4C)CC3)cc2)NC(=O)NC1=O

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HTR2B P41595 4/20 0.62
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ PROKR1 Q8TCW9 1/20 0.42
▸ HSD11B1 P28845 1/20 0.39
▸ CRBN Q96SW2 2/20 0.39
▸ DDB1 Q16531 1/20 0.39
▸ MAPT P10636 2/20 0.39
▸ CNR2 P34972 3/20 0.38
▸ UBE2M P61081 1/20 0.38
▸ DCUN1D1 Q96GG9 1/20 0.38
▸ ADAMTS5 Q9UNA0 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135370 1.00 HTR2B (0.62) HTR2BMEN1KMT2APROKR1HSD11B1
SCHEMBL20135410 0.87 KMT2A (0.61) HTR2BMEN1KMT2ACRBNMAPT
SCHEMBL20135409 0.87 KMT2A (0.61) HTR2BMEN1KMT2ACRBNMAPT
SCHEMBL20135442 0.81 UBE2M (0.63) MEN1KMT2AMAPTUBE2MDCUN1D1
SCHEMBL20135454 0.81 LMNA (0.62) HTR2BMAPTLMNATP53THRB
SCHEMBL20135457 0.81 LMNA (0.62) HTR2BMAPTLMNATP53THRB
SCHEMBL20135441 0.81 UBE2M (0.63) MEN1KMT2AMAPTUBE2MDCUN1D1
SCHEMBL20135136 0.79 NPC1 (0.45) HTR2BHSD11B1CRBNADAMTS5
SCHEMBL20135137 0.79 NPC1 (0.45) HTR2BHSD11B1CRBNADAMTS5
SCHEMBL29688421 0.79 NPC1 (0.45) HTR2BHSD11B1CRBNADAMTS5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 — — CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 — — US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 HTR2B 2669/4885MEN1 3735/4885KMT2A 2568/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 HTR2B 2766/4885MEN1 2913/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.